Lewy
body dementia is
a progressive brain disorder in which Lewy bodies build up in different parts
of the brain that regulate cognition, movement and behavior. Lewy bodies are
abnormal deposition of a protein called alpha-synuclein. The symptoms associated
with the Lewy body dementia includes memory and thinking problems; moving
problems; and sleeping and behavioral changes. It can be treated by
medications, physical therapy, speech therapy, occupational therapy, and
individual and family psychotherapy.
Access
Detailed Report Summary:
Axovant
Sciences Ltd. is in the process of developing a combination of RVT-103 and
RVT-104 for the treatment of Lewy body dementia. Asceneuron SA, and Arena
Pharmaceuticals Inc. are some other key players involved in the development of
drugs for the treatment of Lewy body dementia.
Request
to Get the Sample Pages at:
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment